Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia

Psychiatric Services

Volumn 48, Issue 12, 1997, Pages 1571-1577

  Dellva, Mary Anne ^a   Tran, Pierre ^a   Tollefson, Gary D ^a   Wentley, Anita L ^a   Beasley Jr , Charles M ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OLANZAPINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0030827432     PISSN: 10752730     EISSN: None     Source Type: Journal    
DOI: 10.1176/ps.48.12.1571     Document Type: Article

References (43)

1. Davis JM, Kane JM, Marder SR, et al: Dose response of prophylactic antipsychotics. Journal of Clinical Psychiatry 54(suppl 3):24-30, 1993
2. Gilbert PL, Harris MJ, McAdams LA, et al: Neuroleptic withdrawal in schizophrenic patients. Archives of General Psychiatry 52:173-188, 1995
3. Schooler NR: Maintenance medication for schizophrenia: strategies for dose reduction. Schizophrenia Bulletin 17:311-324, 1991
4. Schooler NR: Reducing dosage in maintenance treatment of schizophrenia. British Journal of Psychiatry 163(suppl 22):58-65, 1993
5. Kane JM, Marder SR: Psychopharmacologic treatment of schizophrenia. Schizophrenia Bulletin 19:287-302, 1993
6. Johnstone EC, Geddes J: How high is the relapse rate in schizophrenia? Acta Psychiatrica Scandinavica 89(suppl 382):6-10, 1994
7. Bymaster FP, Calligaro DO, Falcone JF, et al: Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87-96, 1996
8. 1-adrenergic, and muscarinic receptors in vivo in rats. Psychopharmacology 124:87-94, 1996
9. Fuller RW, Snoddy HD: Neuroendocrine evidence for antagonism of serotonin and dopamine receptor by olanzapine (LY 170053), an antipsychotic drug candidate. Research Communications in Chemical Pathology and Pharmacology 77:87-93, 1992
10. Moore NA, Tye NC, Axton MS, et al: The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. Journal of Pharmacology and Experimental Therapeutics 262:545-551, 1992
11. Arnt J: Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine. European Journal of Pharmacology 283:55-62, 1995
12. Cools AR, Prinssen EPM, Ellenbroek BA: The olfactory tubercle as a site of action of neuroleptics with an atypical profile in the paw test: effect of risperidone, prothipendyl, ORG 5222, sertindole, and olanzapine. Psychopharmacology 119:428-439, 1995
13. Robertson GS, Fibiger HC: Effects of olanzapine on regional C-Fos expression in rat forehrain. Neuropsychopharmacology 14: 105-110, 1996
14. 10 dopamine neurons. Neuropsychopharmacology 14: 97-104, 1996
15. Stockton ME, Rasmussen K: Olanzapine, a novel atypical antipsychotic, reverses damphetamine-induced inhibition of midbrain dopamine cells. Psychopharmacology 124:50-56, 1996
16. Beasley C, Tollefson G, Tran P, et al: Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14:111-123, 1996
17. Beasley C, Sanger T, Satterlee W, et al: Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 124:159-167, 1996
18. Tollefson G, Beasley C, Tran P, et al: Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. American Journal of Psychiatry 154:457-465, 1997
19. Kane JM, Lieberman JA: Maintenance pharmacotherapy in schizophrenia, in Psychopharmacology: The Third Generation of Progress. Edited by Meltzer HY. New York, Raven Press, 1987
20. Crow TJ, MacMillan JE, Johnson AL, et al: A randomised controlled trial of prophylactic neuroleptic treatment. British Journal of Psychiatry 148:120-127 1986
21. Goldstein MJ, Rodnick EH, Evans JR, et al: Drug and family therapy in the aftercare of acute schizophrenics. Archives of General Psychiatry 35:1169-1177, 1978
22. Marder SR, Van Putten T, Mintz J, et al: Costs and benefits of two doses of fluphenazine. Archives of General Psychiatry 41:1025-1029, 1984
23. Marder SR, Van Putten T, Mintz J, et al: Low- and conventional-dose maintenance therapy with fluphenazine decanoate: two-year outcome. Archives of General Psychiatry 44:518-521, 1987
24. Hogarty GE, McEvoy JP, Munitz M, et al: Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Archives of General Psychiatry 45:797-805, 1988
25. Kane JM, Rifkin A, Woerner M, et al: Low-dose neuroleptic treatment of outpatient schizophrenics. Archives of General Psychiatry 40:893-896, 1983
26. Kane JM, Rifkin A, Woerner M, et al: High-dose versus low-dose strategies in the treatment of schizophrenia. Psychopharmacology Bulletin 21:533-537, 1985
27. Kane JM, Woerner M, Sarantakos S: Depot neuroleptics: a comparative review of standard, intermediate, and low-dose regimens. Journal of Clinical Psychiatry 47(suppl 5):30-33, 1986
28. Johnson DAW, Ludlow JM, Street K, et al: Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilised out-patients with schizophrenia. British Journal of Psychiatry 151:634-638, 1987
29. Carpenter WT, Hanlon TE, Heinrichs DW, et al: Continuous versus targeted medication in schizophrenic outpatients: outcome results. American Journal of Psychiatry 147:1138-1148, 1990
30. Herz MI, Glazer WM, Mostert MA, et al: Intermittent vs maintenance medication in schizophrenia. Archives of General Psychiatry 48:333-339, 1991
31. Jolley AG, Hirsch SR, McRink A, et al: Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year. British Medical Journal 298:985-990, 1989
32. Pietzcker A, Gaebel W, Köpcke W, et al: Intermittent versus maintenance neuroleptic long-term treatment in schizophrenia: 2-year results of a German multicenter study. Journal of Psychiatric Research 27:321-339, 1993
33. Diagnostic and Statistical Manual of Mental Disorders, 3rd ed, rev. Washington, DC, American Psychiatric Association, 1987
34. Woerner MG, Mannuzza S, Kane JM: Anchoring the BPRS: an aid to improved reliability. Psychopharmacology Bulletin 24: 112-117, 1988
35. Andreasen NC: Negative symptoms in schizophrenia. Archives of General Psychiatry 39:784-788, 1982
36. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology, revised ed. DHEW pub (ADM)76-338. Rockville, Md, National Institute of Mental Health, 1976
37. Simpson GM, Angus JW: A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica 212(suppl):11-19, 1970
38. Barnes TR: A rating scale for drug-induced akathisia. British Journal of Psychiatry 154:672-676, 1989
39. Kay SR, Opler LA, Fiszbein A: Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY, Multi-Health Systems, 1992
40. Beasley CM, Hamilton SH, Crawford AM, et al: Olanzapine versus haloperidol: acute-phase results of the international double-blind olanzapine trial. European Neuropsychopharmacology 7:125-137, 1997
41. SAS/STAT User's Guide, Version 6, 4th ed, vol 1 and 2. Cary, NC, SAS Institute, 1989
42. Greenhouse JB, Meyer MM: A note on randomization and selection bias in maintenance therapy clinical trials. Psychopharmacology Bulletin 27(3):225-229, 1991
43. Greenhouse JB, Stangl D, Kupfer DJ, et al: Methodologic issues in maintenance therapy clinical trials. Archives of General Psychiatry 48:313-318, 1991